S-1/A: Liminatus Pharma Completes SPAC Merger, Faces Funding Challenges

Liminatus Pharma, a pre-clinical stage biotech, completed its business combination with Iris Acquisition Corp., securing initial funding but still faces significant capital needs and a going concern warning.

Summary

• Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) completed its Business Combination with Iris Acquisition Corp. on April 30, 2025, becoming a publicly traded company on Nasdaq under the symbol LIMN.
• The company is a pre-clinical stage, pre-revenue biopharmaceutical company focused on developing a next-generation CD47 immune checkpoint inhibitor (IBA101) for advanced solid cancers, including non-small cell lung cancer (NSCLC).
• A PIPE Equity Investment of $15,000,000 was completed concurrently with the Business Combination, involving the issuance of 1,500,000 shares of ParentCo Common Stock at $10.00 per share.
• The company reported a net loss of $0.3 million for the three months ended March 31, 2025, and an accumulated deficit of $29.0 million as of March 31, 2025.
• Liminatus Pharma, LLC (the accounting acquirer) had cash of approximately $35,000 as of March 31, 2025, and total short-term debt to related parties of $20.686 million.
• Pro forma combined financial information shows a net loss of $(2,891) thousand for the three months ended March 31, 2025, and pro forma cash of $11,256 thousand.
• The CD47 asset (IBA101) has completed key preclinical studies, including CMC development and monkey toxicity studies, and is preparing for an IND application for a Phase 1 clinical trial in 2025.
• The company's CD47 antibody is designed to preferentially bind to immune cells, not red blood cells or platelets, aiming to avoid anemia and thrombocytopenia seen with first-generation CD47 inhibitors like Magrolimab.
• New potential therapeutic applications for the CD47 asset beyond cancer include reducing chronic inflammation and inducing weight loss, with promising early results from animal studies in high-fat diet mice.
• The company's TDT licenses (CAR-T and Vaccine) were terminated in August 2024, and negotiations are ongoing regarding $2.2 million owed to TDT.
• The current market price of Liminatus Common Stock was $6.47 per share and Public Warrants were $0.2775 per warrant as of July 23, 2025, while the warrant exercise price is $11.50, making cash exercise currently unfavorable.
• Selling Securityholders are registering for resale up to 20,454,961 shares of Common Stock, representing approximately 72.5% of total outstanding shares, which could lead to significant market price decline.
• The company has identified a material weakness in its internal control over financial reporting as of December 31, 2024, which remains unremediated as of March 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's pre-revenue status, significant accumulated losses, explicit 'going concern' warning, and reliance on future capital raises. While the product candidate shows promise and has a differentiating feature, the financial instability and early stage of development present substantial risks. The low stock price relative to warrant exercise price further dampens immediate financial prospects.

Positives

• Successfully completed the Business Combination, transitioning to a public company listed on Nasdaq.
• Secured a $15,000,000 PIPE Equity Investment, providing initial capital for operations.
• The lead product candidate, IBA101 (next-generation CD47 immune checkpoint inhibitor), has a key differentiating feature of not binding to red blood cells or platelets, potentially avoiding severe side effects like anemia seen with prior CD47 inhibitors.
• Key preclinical studies (CMC development, monkey toxicity) for IBA101 have been completed, enabling swift preparation for IND application and clinical trials.
• IBA101 has shown synergistic anti-tumor responses in animal models when combined with anti-PD1 antibody and other immune checkpoint inhibitors.
• New potential therapeutic applications for IBA101 beyond cancer, such as reducing chronic inflammation and inducing weight loss, were discovered in animal studies, expanding its market potential.
• The company's leadership team has extensive global experience in the biopharma industry, spanning development, commercialization, and financing.

Negatives

• The company is a pre-clinical stage, pre-revenue entity with a history of significant operating losses and an accumulated deficit of $29.0 million as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash to fund operations for the next twelve months.
• The company has not generated any revenue from product sales to date and does not expect to in the foreseeable future.
• The current cash balance of approximately $35,000 as of March 31, 2025, is extremely low, necessitating substantial additional funding.
• The company carries significant short-term debt of $20.686 million to related parties as of March 31, 2025, with repayment deferred by mutual agreement.
• The TDT licenses (CAR-T and Vaccine products), which were part of the initial pipeline, were terminated in August 2024, narrowing the product focus.
• The current market price of Common Stock ($6.47) is significantly below the warrant exercise price ($11.50), making it unlikely the company will receive cash proceeds from warrant exercises.
• A material weakness in internal control over financial reporting was identified as of December 31, 2024, and remains unremediated as of March 31, 2025.
• Sales of a substantial amount of Common Stock (72.5% of outstanding shares) by Selling Securityholders could cause a significant decline in the market price.
• The management team has limited historical experience with the company's specific clients, business, and industry, which may impact execution.

Risks

• Liminatus is a pre-clinical stage biotechnology company with a limited operating history and no products approved for commercial sale, making future success and viability difficult to evaluate.
• Expects to continue incurring significant losses for the foreseeable future and may never achieve or maintain profitability.
• Recurring losses from operations and financial condition raise substantial doubt about the ability to continue as a going concern.
• Clinical development is a lengthy, expensive, and uncertain process, and results of earlier studies may not be predictive of future trial results.
• Requires substantial additional funds to advance development; inability to raise capital could force delays, reductions, or elimination of development programs.
• Business relies on certain intellectual property rights that can be terminated in certain circumstances, and the Business Combination may be considered a change of control under some licenses.
• Business, operations, and clinical development plans could be adversely affected by health crises (e.g., pandemics), business interruptions, staffing shortages, and supply chain issues.
• Has never successfully completed the regulatory approval process for any product candidates.
• Substantially dependent on the success of the Liminatus assets (CD47 immune checkpoint inhibitor), and anticipated clinical trials may not be successful.
• Product candidates may have a safety profile that could prevent regulatory approval, marketing approval, or market acceptance, or limit commercial potential.
• Faces substantial competition from larger pharmaceutical and biotechnology companies with greater resources and experience.
• May not have patent rights or other proprietary rights sufficient to maintain exclusivity, or may not be able to prevent competitive products.
• Intellectual property rights may not be protected throughout the world, and changes in patent laws could diminish their value.
• Failure to comply with obligations in license agreements could lead to loss of development and commercialization rights.
• Third parties may allege infringement of their intellectual property rights, leading to costly and time-consuming legal proceedings.
• Inability to protect confidential information and trade secrets would harm business and competitive position.
• Ongoing regulatory obligations and continued regulatory review may result in significant additional expense and penalties for non-compliance.
• Healthcare legislative reform measures aimed at reducing costs may adversely impact business and results of operations.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Failure to comply with privacy and data protection laws (e.g., GDPR, CCPA) could lead to enforcement actions, litigation, and adverse publicity.
• There may not be enough liquidity in the company's securities to enable stockholders to sell their securities.
• The market price of equity securities may be volatile, and investors could lose a significant part of their investment.
• The requirements of being a public company may strain resources and distract management, incurring substantial costs.
• No intention to pay cash dividends in the foreseeable future.
• If shares become subject to penny stock rules, it would become more difficult to trade.
• Anti-takeover provisions in the certificate of incorporation and bylaws could impair a takeover attempt.
• Exclusive forum provisions in the charter could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company plans to substantially increase research and development expenses as it develops its CD47 immune checkpoint inhibitor (IBA101) and other product candidates, and seeks regulatory approval. A Phase 1 clinical trial for IBA101 in advanced solid cancers is scheduled for 2025, with a global Phase 1 trial in South Korea focusing on lung cancer patients. A combination therapy trial (IBA101 + Durvalumab or Pembrolizumab) for stage III NSCLC is planned for 2027. The company intends to pursue business development, strategic partnerships, and in-licensing additional promising therapeutic assets to broaden its portfolio. It expects to incur significant commercialization expenses if products receive marketing approval.

Management Comments

• Management believes the net proceeds from the Business Combination will not be sufficient to fund operating expenses and capital requirements through at least the next twelve months.
• Management plans to raise additional cash through equity and debt financings or other arrangements to fund operations.
• Management believes its leadership team's extensive global experience in the biopharma industry is a key competitive advantage.
• Management believes the CD47 next generation antibody's preferential binding to immune cells, not red blood cells and platelets, is a key differentiating feature.

Industry Context

The company operates in the highly competitive and rapidly evolving biotechnology and oncology industries, characterized by strong emphasis on intellectual property. Its focus on CD47 immune checkpoint inhibitors places it in a field where first-generation agents (like Magrolimab by Gilead Sciences) faced significant setbacks due to efficacy and safety concerns (e.g., anemia). Liminatus aims to differentiate its product (IBA101) by addressing these safety issues (avoiding RBC binding). The global market for PD-1/PD-L1 blockades, which CD47 inhibitors are expected to complement, was estimated at $49.5 billion in 2023 and is projected to reach $123.3 billion by 2033, indicating a large potential market if successful. The shift by pioneers like Dr. Irving Weissman to explore CD47 blockers for non-cancer indications (e.g., cardiovascular diseases) aligns with Liminatus's own findings of broader applications for IBA101 in chronic inflammation and weight loss.

Comparison to Industry Standards

• Liminatus's CD47 program (IBA101) is designed to avoid red blood cell binding and prevent anemia, a common and significant safety concern with first-generation CD47 inhibitors like Magrolimab (developed by Forty Seven, acquired by Gilead Sciences). Magrolimab's clinical development faced substantial setbacks and trial terminations due to efficacy and safety issues, including anemia.
• The company's preclinical in vivo studies show synergistic effects when its CD47 antibody is combined with marketed PD-1/PD-L1 blockades (e.g., Durvalumab, Pembrolizumab) and T-cell boosters (LAG-3, TIGIT, TIM-3, ICOS blockades), suggesting a versatile approach compared to standalone treatments.
• The global market for PD-1/PD-L1 blockades, a relevant comparison for combination therapies, was estimated at $49.5 billion in 2023 and is projected to reach $123.3 billion by 2033, indicating a substantial market opportunity if Liminatus's combination strategy is successful.
• Unlike some established biopharmaceutical companies, Liminatus is a pre-clinical stage, pre-revenue company with a limited operating history and no commercialized products, placing it at a much earlier and riskier stage of development compared to industry leaders.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.

Related Party Transactions

• Completed Business Combination with Iris Acquisition Corp., a SPAC.
• Received a PIPE Equity Investment of $15,000,000 from an accredited investor (PIPE Investor).
• Sponsor (Iris Acquisition Holdings LLC) forfeited 4,177,778 Private Placement Warrants upon Business Combination closing.
• Liminatus Pharma, LLC has significant short-term debt to related parties totaling $20.686 million as of March 31, 2025, including loans from Feelux Co., Ltd., Car-Tcellkor, Inc., Valetudo Therapeutics LLC, Ewon Comfortech Co., Ltd., Prophase Sciences LLC, Hana Immunotherapeutics, LLC, and Amantes LLC. Repayment of past due loans has been mutually deferred.
• Liminatus Pharma, LLC has a loan receivable from Iris Acquisition Corp. (now a wholly-owned subsidiary) of $4.244 million as of March 31, 2025.
• Chris Kim, the CEO, is owed $0.2 million for compensation as of December 31, 2024 and 2023, and is also the CEO of Viral Gene, Inc., which has a loan due from Liminatus.
• Iris Acquisition Corp. had an administrative support agreement with Arrow Capital Management LLC, a related party, incurring $90,000 for the three months ended March 31, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future capital raises and potential downward pressure on share price due to a large percentage of shares (72.5%) registered for resale by Selling Securityholders. Current stock price is below warrant exercise price, limiting potential upside from warrant exercises. The 'going concern' warning indicates substantial risk to investment.
• **Employees:** The company is highly dependent on key personnel, and successful integration of new management team members is crucial. Future growth plans will require hiring additional personnel, which could create new opportunities.
• **Customers (future):** Potential for novel cancer therapies (CD47 inhibitor) and broader applications in chronic inflammation and weight loss could offer new treatment options.
• **Suppliers/Creditors:** Existing related-party creditors have deferred repayment, indicating a reliance on future funding. The company's financial instability could pose risks to future supplier relationships.
• **Regulatory Bodies:** The company is subject to extensive regulatory scrutiny and compliance requirements, with potential penalties for non-compliance.

Next Steps

• Prepare and submit an Investigational New Drug (IND) application for IBA101.
• Initiate a Phase 1 clinical trial for IBA101 in advanced solid cancers in 2025, with a focus on lung cancer patients in South Korea.
• Initiate a global Phase 1 clinical trial for IBA101 in combination with Durvalumab or Pembrolizumab for stage III NSCLC in South Korea in 2027.
• Conduct additional preclinical animal studies utilizing mouse lung cancer cell lines (e.g., LL/2) if requested by the FDA.
• Continue to raise additional capital through equity and debt financings or other arrangements.
• Negotiate and finalize agreements with TDT regarding the $2.2 million owed after license termination.
• Remediate the identified material weakness in internal control over financial reporting.
• Seek to selectively form collaborations to expand capabilities and accelerate R&D activities.
• Actively evaluate additional assets for in-licensing or partnership to broaden the portfolio.
• Continue extending the global intellectual property portfolio to protect assets.

Key Dates

Recommendation

The company is a pre-clinical stage, pre-revenue entity with a substantial accumulated deficit and an explicit 'going concern' warning from its auditors. While the completion of the SPAC merger and a PIPE investment provide some capital, the current cash position is insufficient for long-term operations, and the stock price is significantly below the warrant exercise price, making future cash from warrants unlikely. The large volume of shares registered for resale by insiders (72.5% of outstanding shares) creates significant downward pressure on the stock. The termination of previous license agreements further concentrates risk on a single, early-stage asset. Given the high financial risk, lack of immediate revenue prospects, and potential for further dilution and price volatility, a seasoned investor would likely recommend selling or avoiding this stock.

Keywords

Biotechnology, Oncology, CD47, Immune Checkpoint Inhibitor, IBA101, Pre-clinical, Drug Development, Cancer Therapy, Nasdaq, SPAC, Merger, Biopharmaceutical, Solid Cancers, NSCLC, Anemia Avoidance, Inflammation, Weight Loss, Intellectual Property, Going Concern, PIPE Investment